

Clinical trial registration statement: As we said in the main body, our article "Safety and efficacy of a PD-1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers" is a retrospective analysis. We retrospectively collected 89 patients from January 2020 to December 2021 for analysis. Prospective assignment of patients was not involved in our study, so we should not need to submit this document.